KR102815607B1 - 전사 활성화 단백질의 이미다조피페라진 억제제 - Google Patents

전사 활성화 단백질의 이미다조피페라진 억제제 Download PDF

Info

Publication number
KR102815607B1
KR102815607B1 KR1020207031004A KR20207031004A KR102815607B1 KR 102815607 B1 KR102815607 B1 KR 102815607B1 KR 1020207031004 A KR1020207031004 A KR 1020207031004A KR 20207031004 A KR20207031004 A KR 20207031004A KR 102815607 B1 KR102815607 B1 KR 102815607B1
Authority
KR
South Korea
Prior art keywords
mmol
compound
methyl
delete delete
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207031004A
Other languages
English (en)
Korean (ko)
Other versions
KR20210003764A (ko
Inventor
캉 레
마이클 제이 소스
필립 존스
제이슨 크로스
크리스토퍼 엘 캐롤
티모시 제이 맥카푸스
피유스 케이 맨덜
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20210003764A publication Critical patent/KR20210003764A/ko
Application granted granted Critical
Publication of KR102815607B1 publication Critical patent/KR102815607B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207031004A 2018-03-29 2019-03-29 전사 활성화 단백질의 이미다조피페라진 억제제 Active KR102815607B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650151P 2018-03-29 2018-03-29
US62/650,151 2018-03-29
PCT/US2019/024976 WO2019191667A1 (en) 2018-03-29 2019-03-29 Imidazopiperazine inhibitors of transcription activating proteins

Publications (2)

Publication Number Publication Date
KR20210003764A KR20210003764A (ko) 2021-01-12
KR102815607B1 true KR102815607B1 (ko) 2025-05-30

Family

ID=68057632

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031004A Active KR102815607B1 (ko) 2018-03-29 2019-03-29 전사 활성화 단백질의 이미다조피페라진 억제제

Country Status (12)

Country Link
US (3) US11058688B2 (https=)
EP (1) EP3773587A4 (https=)
JP (1) JP7387627B2 (https=)
KR (1) KR102815607B1 (https=)
CN (1) CN112165944B (https=)
AU (2) AU2019245403B2 (https=)
BR (1) BR112020019824A2 (https=)
CA (1) CA3095367A1 (https=)
IL (1) IL277628A (https=)
RU (1) RU2020131507A (https=)
WO (1) WO2019191667A1 (https=)
ZA (1) ZA202006092B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020131507A (ru) 2018-03-29 2022-05-04 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
KR102939417B1 (ko) 2020-04-25 2026-03-17 파마블럭 사이언시스 (난징), 인코포레이티드 Cbp/ep 300 억제제 및 이의 용도
EP4221708A4 (en) 2020-10-02 2024-11-06 Board of Regents, The University of Texas System IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS
CA3193745A1 (en) * 2020-10-02 2022-04-07 Kang Le Imidazopiperazine inhibitors of transcription activating proteins
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
CN121851016A (zh) * 2021-04-21 2026-04-14 长春金赛药业有限责任公司 含咪唑稠环类衍生物、其制备方法及其在医药上的应用
CN113429427A (zh) * 2021-07-05 2021-09-24 湖南南新制药股份有限公司 杂环化合物及其制备方法和药物用途
CN115724857B (zh) * 2021-08-25 2024-06-21 杭州禹泓医药科技有限公司 一种芳杂环类化合物、含其的药物组合物及其应用
CN116410211A (zh) * 2021-12-29 2023-07-11 山东新时代药业有限公司 一种苯并呋喃类化合物
CN116478130B (zh) * 2022-01-21 2025-05-30 深圳默元生物科技有限公司 N-羟基喹啉甲酰胺化合物及其用途
WO2023235809A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company Cgas inhibitors
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530891A (ja) 2007-06-21 2010-09-16 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
JP2011508735A (ja) 2007-12-26 2011-03-17 ジエンス ヘンルイ メデイシンカンパニー リミテッド テトラヒドロ・イミダゾ［１，５−α］ピラジン誘導体、その調製プロセスおよび医薬的使用
US20110190292A1 (en) 2006-11-27 2011-08-04 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
JP2013535491A (ja) 2010-08-09 2013-09-12 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド フタラジノンケトン誘導体、その製造法および医薬用途
WO2014199171A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
JP2017537100A (ja) 2014-11-27 2017-12-14 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP2018502136A (ja) 2015-01-16 2018-01-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染性疾患を処置するためのピラジン化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
MX2008015008A (es) 2006-05-26 2008-12-05 Novartis Ag INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
WO2008078291A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN102076694A (zh) 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物
PE20120121A1 (es) * 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
US9145418B2 (en) 2011-10-07 2015-09-29 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
CN103087067A (zh) * 2012-08-02 2013-05-08 盛世泰科生物医药技术(苏州)有限公司 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途
US9695176B2 (en) 2012-10-18 2017-07-04 Bristol-Myers Squibb Company Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists
WO2014206150A1 (en) * 2013-06-28 2014-12-31 Abbvie Inc. Bromodomain inhibitors
JP6820254B2 (ja) 2014-10-10 2021-01-27 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
JP7014736B2 (ja) 2016-05-24 2022-02-01 ジェネンテック， インコーポレイテッド がんの処置のためのピラゾロピリジン誘導体
EP3464270B1 (en) 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
RU2020131507A (ru) 2018-03-29 2022-05-04 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110190292A1 (en) 2006-11-27 2011-08-04 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
JP2010530891A (ja) 2007-06-21 2010-09-16 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
JP2011508735A (ja) 2007-12-26 2011-03-17 ジエンス ヘンルイ メデイシンカンパニー リミテッド テトラヒドロ・イミダゾ［１，５−α］ピラジン誘導体、その調製プロセスおよび医薬的使用
JP2013535491A (ja) 2010-08-09 2013-09-12 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド フタラジノンケトン誘導体、その製造法および医薬用途
WO2014199171A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
JP2017537100A (ja) 2014-11-27 2017-12-14 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP2018502136A (ja) 2015-01-16 2018-01-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 感染性疾患を処置するためのピラジン化合物

Also Published As

Publication number Publication date
CN112165944A (zh) 2021-01-01
US20190298729A1 (en) 2019-10-03
AU2025202971A1 (en) 2025-05-15
US11058688B2 (en) 2021-07-13
ZA202006092B (en) 2022-11-30
WO2019191667A1 (en) 2019-10-03
AU2019245403A1 (en) 2020-10-22
CN112165944B (zh) 2024-04-09
US20230008047A1 (en) 2023-01-12
RU2020131507A (ru) 2022-05-04
US12186324B2 (en) 2025-01-07
EP3773587A1 (en) 2021-02-17
JP2021519308A (ja) 2021-08-10
KR20210003764A (ko) 2021-01-12
EP3773587A4 (en) 2021-09-29
JP7387627B2 (ja) 2023-11-28
US20250127792A1 (en) 2025-04-24
CA3095367A1 (en) 2019-10-03
IL277628A (en) 2020-11-30
BR112020019824A2 (pt) 2021-01-05
AU2019245403B2 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
KR102815607B1 (ko) 전사 활성화 단백질의 이미다조피페라진 억제제
JP7128816B2 (ja) 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
JP7601788B2 (ja) チロシンキナーゼの複素環式阻害剤
US10899769B2 (en) Imidazopiperazinone inhibitors of transcription activating proteins
JP2019517487A (ja) Ｐｔｐｎ１１の複素環式阻害剤
US12559497B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
KR20160104729A (ko) 암 또는 염증성 질환의 치료를 위한 치환 피롤로피리딘 및 피롤로피라진
US12540139B2 (en) Imidazopiperazine inhibitors of transcription activating proteins
WO2018213777A1 (en) Heterocyclic inhibitors of kdm5 for the treatment of disease
WO2020219906A1 (en) Heterocyclic inhibitors of tyrosine kinase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201027

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220322

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240613

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250317

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250528

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250528

End annual number: 3

Start annual number: 1

PG1601 Publication of registration